TRACON Pharmaceuticals is thrilled to announce a groundbreaking milestone in its journey towards innovation. On November 20, 2023, the company successfully licensed its exceptional product development platform, marking a significant step forward in the pharmaceutical industry. In exchange for this remarkable achievement, TRACON Pharmaceuticals received an upfront payment of $3 million.
This exclusive agreement grants TRACON Pharmaceuticals a non-transferable and non-exclusive license, showcasing the immense value and potential of their product development platform. With this license in hand, TRACON Pharmaceuticals is now poised to revolutionize the field of medicine, paving the way for groundbreaking advancements and discoveries.
But the benefits don’t stop there. As part of this momentous deal, TRACON Pharmaceuticals stands to gain even greater rewards. The company is eligible to receive development and regulatory milestones worth up to an astonishing $10.5 million, along with additional commercial sales milestones. These potential milestones serve as a testament to the immense potential and market demand for TRACON Pharmaceuticals’ product development capabilities.
This strategic move by TRACON Pharmaceuticals not only enhances their reputation as a leader in the pharmaceutical industry but also opens up new avenues for generating additional revenue streams. By leveraging their product development capabilities, TRACON Pharmaceuticals is poised to transform the landscape of healthcare, improving the lives of countless individuals worldwide.
The licensing of TRACON Pharmaceuticals’ product development platform is a game-changer, propelling the company towards an exciting future filled with innovation and success. As the world eagerly awaits the groundbreaking advancements that will emerge from this collaboration, it is clear that TRACON Pharmaceuticals is at the forefront of revolutionizing the way we approach medicine.
TRACON Pharmaceuticals, Inc.
TCON
Neutral
Updated on: 04/12/2023
Financial Health
Weak
Debt to equity ratio: Strong Sell
Price to earnings ratio: Sell
Price to book ratio: Strong Sell
DCF: Strong Buy
ROE: Strong Buy
TCON Stock: Positive Growth and Promising Future in Health Technology Sector
TCON stock had a previous close of $0.17 on November 20, 2023. The stock opened at $0.19 and had a day’s range of $0.17 to $0.19. The trading volume for the day was 252,268 shares. The average volume over the past three months was 1,983,444 shares. The market capitalization of TCON was $5.1 million. TCON had a positive growth rate of 16.18% in the previous year and a higher growth rate of 55.40% in the current year. However, there is no information available about the projected earnings growth for the next five years. TCON had a negative revenue growth rate of 100.00% in the last year. The price-to-earnings (P/E) ratio for TCON is not available (NM), and there is no information about the price/sales ratio or price/book ratio. TCON operates in the health technology sector and is categorized under pharmaceuticals: major industry. TCON’s corporate headquarters are located in San Diego, California. The next reporting date for TCON is February 29, 2024. The earnings per share (EPS) forecast for the current quarter is -$0.22. The company reported zero annual revenue for the previous year and a net loss of $29.1 million.
TRACON Pharmaceuticals Inc (TCON) Stock Forecast: Potential Increase of +2,060.99% and Consensus Buy Recommendation
On November 20, 2023, TRACON Pharmaceuticals Inc (TCON) had a median target price forecast of $4.00, with a high estimate of $7.00 and a low estimate of $1.00. This indicates a potential increase of +2,060.99% from the last recorded price of $0.19.
According to the consensus among three polled investment analysts, the recommendation for TRACON Pharmaceuticals Inc stock is to buy. This rating has remained steady since November.
TRACON Pharmaceuticals Inc reported earnings per share of -$0.22 for the current quarter, with sales of $2.3 million. The reporting date for these figures was February 29.
Investors should consider the positive sentiment surrounding TRACON Pharmaceuticals Inc, but conduct further research and analysis before making investment decisions.
Discussion about this post